Blood Glucose Control

Is it true that individuals paying for diabetes care and management using fee-for-service clinics may have better outcomes in their glucose levels?

Woman, 55 years of age visited with me 3 weeks ago. Her glucose levels were in the 200-250 mg/dL range. She was actually a new patient of ours; her A1C was 9.2%. We recommended a CGM. She purchased one and brought it to the office for me to teach her how to use it. I did so. This patient is well-educated and seemed tech-savvy. When she left the visit, she "seemed" to understand CGM, what it is, what to do, and how to insert the sensor, get readings, interpret readings, etc.

In part 1 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the work done in partnership with the ADA regarding findings among patients with diabetes and their use of medications.

In part 2 of this Exclusive Interview, Lisa Latts explains the process behind the artificial intelligence Watson in a conversation with Diabetes in Control Publisher Steve Freed.

In part 3 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the personalization of medicine as the future of diabetes care.

In part 4 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the genesis of Watson and the work currently in the pipeline.

In part 5 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the findings from the cardiovascular study for use in Watson.

In part 6 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about her desire to make the healthcare system work more effectively and improve the practice of medicine.

In part 7, the conclusion of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the Watson tools available and how to access them.

Study assesses glycemic variability via continuous glucose monitoring and compares it against incidence of diabetic retinopathy to determine if correlation exists.